Switch to:
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Research and Development
$1,456 Mil (TTM As of Jun. 2014)

This is the expense the company spent on research and development. Teva Pharmaceutical Industries Ltd's research and development for the three months ended in Jun. 2014 was $344 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2014 was $1,456 Mil.


Definition

This is the expense the company spent on research and development.

Teva Pharmaceutical Industries Ltd Research & Development for the trailing twelve months (TTM) ended in Jun. 2014 was 348 (Sep. 2013 ) + 411 (Dec. 2013 ) + 353 (Mar. 2014 ) + 344 (Jun. 2014 ) = $1,456 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Teva Pharmaceutical Industries Ltd Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Research & Development 3383694955812,1888029511,0951,3561,427

Teva Pharmaceutical Industries Ltd Quarterly Data

Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14
Research & Development 292298324442329339348411353344
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK